Quantcast
Channel: Games
Viewing all articles
Browse latest Browse all 16760

THQ Nordic acquires developer Experiment 101 and Biomutant game

$
0
0

THQ Nordic today announced that it has acquired 100 percent of the shares from developer Experiment 101, as well as the intellectual property of Biomutant.

Biomutant is an upcoming open world, post-apocalyptic, kung-fu fable. It features anthropomorphic animals in a desperate struggle for survival. Experiment 101 is currently working on Biomutant for Xbox One, PC, and PlayStation 4. The title is scheduled to launch in 2018, but aside from that, we don't know much about the project.

The game was one of the biggest surprises to come out of Gamescom 2017 due to its visuals and gameplay. From the trailer, it seems as though you can alter your appearance and skills if you're exposed to a particular mutagen. The fox-like character's hand turns into one resembling a salamander's after he touches a mysterious substance.

THQ Nordic announced the acquisition on Twitter and many gamers thought this was a promising move. If the developers are able to deliver a polished "AAA" game with that concept, it might resonate well with consumers. However, other individuals were skeptical. When jokingly asked if THQ Nordic were pulling an "EA", the publisher's Twitter handle said that they didn't close a studio before acquiring a new one.

This, of course, refers to EA's decision to close Visceral Games and alter their single-player Star Wars game before they acquired Titanfall developers Respawn Entertainment. It seems like EA can't catch a break no matter what. In response to the loot crate controversy the company announced that they were pulling microtransactions. However, they'll be back at a later date when DICE can make the necessary balancing changes.

Keep an eye on WindowsCentral.com/Gaming for all the latest in Xbox and Windows 10 gaming, accessories, news, and reviews!


Viewing all articles
Browse latest Browse all 16760

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>